Your browser doesn't support javascript.
loading
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga, Ainhoa; Garg, Swati; Tchrakian, Nairi; Dhani, Neesha C; Jimenez, Waldo; Welch, Stephen; MacKay, Helen; Ethier, Josee-Lyne; Gilbert, Lucy; Li, Xuan; Rodriguez, Angela; Chan, Lucy; Bowering, Valerie; Clarke, Blaise; Zhang, Tong; King, Ian; Downs, Gregory; Stockley, Tracy; Wang, Lisa; Udagani, Smitha; Oza, Amit M; Lheureux, Stephanie.
Afiliación
  • Madariaga A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Garg S; University of Toronto, Toronto, ON, Canada.
  • Tchrakian N; Autonomous University of Barcelona, Barcelona, Spain.
  • Dhani NC; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.
  • Jimenez W; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Welch S; University of Toronto, Toronto, ON, Canada.
  • MacKay H; Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada.
  • Ethier JL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Gilbert L; University of Toronto, Toronto, ON, Canada.
  • Li X; Division of Gynecologic Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada.
  • Rodriguez A; Division of Medical Oncology and Hematology, London Health Sciences Center, London Regional Cancer Program, London, ON, Canada.
  • Chan L; Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Bowering V; Division of Medical Oncology and Hematology, Kingston Health Sciences Cancer Centre, Kingston, ON, Canada.
  • Clarke B; Division of Gynecologic Oncology, McGill University Health Centre, Royal Victoria Hospital, Montréal, QC, Canada.
  • Zhang T; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • King I; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Downs G; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Stockley T; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Wang L; University of Toronto, Toronto, ON, Canada.
  • Udagani S; Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada.
  • Oza AM; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
  • Lheureux S; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Nat Commun ; 14(1): 1452, 2023 03 15.
Article en En | MEDLINE | ID: mdl-36922497
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Endometriales / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Endometriales / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: Canadá